Key result
Administration of olmesartan ameliorated cognitive decline, enhanced cerebral surface blood flow, and reduced oxidative stress in hRN/hANG-Tg mice, whereas hydralazine did not.
Why the study?
Does olmesartan improve cognitive function in human renin/angiotensinogen transgenic mice compared to hydralazine or no treatment?
Does olmesartan improve cognitive function in human renin/angiotensinogen transgenic mice compared to hydralazine or no treatment?
Continuous activation of the brain renin-angiotensin system impairs cognitive function via AT1 receptor stimulation, which can be ameliorated by olmesartan but not hydralazine.
No immediate implications for human cognitive impairment; leaves open whether ARBs confer benefits beyond BP lowering.
We examined the possibility that continuous activation of the human brain renin-angiotensin system causes cognitive impairment, using human renin (hRN) and human angiotensinogen (hANG) gene chimeric transgenic (Tg) mice. Cognitive function was evaluated by the shuttle avoidance test once a week from 10 to 20 weeks of age. The avoidance rate in wild-type mice gradually increased. In contrast, the avoidance rate in chimeric hRN/hANG-Tg mice also increased; however, no further increase in avoidance rate was observed from 14 weeks of age, and it decreased thereafter. Cerebral surface blood flow was markedly reduced in 20-week-old hRN/hANG-Tg mice. Superoxide anion production in the brain was already higher in 10-week-old hRN/hANG-Tg mice and further increased thereafter with an increase in NADPH oxidase activity. Moreover, expression of p47(phox) and Nox4 in the brain of hRN/hANG-Tg mice also increased. Administration of an angiotensin II type 1 receptor blocker, olmesartan (5.0 mg/kg per day), attenuated the increase in blood pressure and ameliorated cognitive decline with enhancement of cerebral surface blood flow and a reduction of oxidative stress in hRN/hANG-Tg mice. On the other hand, hydralazine (0.5 mg/kg per day) did not improve the decrease in avoidance rate, and did not influence cerebral surface blood flow or oxidative stress in hRN/hANG-Tg mice, in spite of a similar reduction of blood pressure to that by olmesartan. Moreover, we observed that treatment with Tempol improved impaired cognitive function in hRN/hANG-Tg mice. These results suggest that continuous activation of the brain renin-angiotensin system impairs cognitive function via stimulation of the angiotensin II type 1 receptor with a decrease in cerebral surface blood flow and an increase in oxidative stress.
No takes yet. Share an insight, caveat, or question.
Inaba et al. (2008) studied Cognitive impairment. Olmesartan vs. Hydralazine or wild-type mice was evaluated on Cognitive function evaluated by the shuttle avoidance test. Administration of olmesartan ameliorated cognitive decline, enhanced cerebral surface blood flow, and reduced oxidative stress in hRN/hANG-Tg mice, whereas hydralazine did not.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: